Expert Commentary on the product profile of Loncastuximab Tesirine
Cancer Network,
In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of…
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Overview of attention for article published in Hematological Oncology, June 2021
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (67th percentile)
-
Good Attention Score compared to outputs of the same age and source (77th percentile)
Readers on
- mendeley
- 5 Mendeley